Your browser doesn't support javascript.
loading
Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
Ling, Walter; Hillhouse, Maureen P; Saxon, Andrew J; Mooney, Larissa J; Thomas, Christie M; Ang, Alfonso; Matthews, Abigail G; Hasson, Albert; Annon, Jeffrey; Sparenborg, Steve; Liu, David S; McCormack, Jennifer; Church, Sarah; Swafford, William; Drexler, Karen; Schuman, Carolyn; Ross, Stephen; Wiest, Katharina; Korthuis, P Todd; Lawson, William; Brigham, Gregory S; Knox, Patricia C; Dawes, Michael; Rotrosen, John.
Afiliación
  • Ling W; University of California, Los Angeles, CA, USA.
  • Hillhouse MP; University of California, Los Angeles, CA, USA.
  • Saxon AJ; Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
  • Mooney LJ; University of California, Los Angeles, CA, USA.
  • Thomas CM; University of California, Los Angeles, CA, USA.
  • Ang A; University of California, Los Angeles, CA, USA.
  • Matthews AG; The Emmes Corporation, Rockville, MD, USA.
  • Hasson A; University of California, Los Angeles, CA, USA.
  • Annon J; University of California, Los Angeles, CA, USA.
  • Sparenborg S; National Institute on Drug Abuse, Bethesda, MD, USA.
  • Liu DS; National Institute on Drug Abuse, Bethesda, MD, USA.
  • McCormack J; The Emmes Corporation, Rockville, MD, USA.
  • Church S; Albert Einstein College of Medicine, Bronx, NY, USA.
  • Swafford W; Addiction Research and Treatment Services (ARTS), Denver, CO, USA.
  • Drexler K; Atlanta VA Medical Center, Atlanta, GA, USA.
  • Schuman C; BAART Programs, San Francisco, CA, USA.
  • Ross S; Bellevue Hospital Center, New York, NY, USA.
  • Wiest K; CODA, Portlad, OR, USA.
  • Korthuis PT; Oregon Health and Science University, Portland, OR, USA.
  • Lawson W; Howard University, Washington, DC, USA.
  • Brigham GS; Maryhaven Treatment Center, Columbus, OH, USA.
  • Knox PC; Recovery Centers of King County (RCKC), Kent, WA, USA.
  • Dawes M; South Texas Veterans Health Care System, San Antonio, TX, USA.
  • Rotrosen J; New York University School of Medicine, New York, NY, USA.
Addiction ; 111(8): 1416-27, 2016 08.
Article en En | MEDLINE | ID: mdl-26948856
AIMS: To examine the safety and effectiveness of buprenorphine + naloxone sublingual tablets (BUP, as Suboxone(®) ) provided after administration of extended-release injectable naltrexone (XR-NTX, as Vivitrol(®) ) to reduce cocaine use in participants who met DSM-IV criteria for cocaine dependence and past or current opioid dependence or abuse. METHODS: This multi-centered, double-blind, placebo-controlled study, conducted under the auspices of the National Drug Abuse Treatment Clinical Trials Network, randomly assigned 302 participants at sites in California, Oregon, Washington, Colorado, Texas, Georgia, Ohio, New York and Washington DC, USA to one of three conditions provided with XR-NTX: 4 mg/day BUP (BUP4, n = 100), 16 mg/day BUP (BUP16, n = 100, or no buprenorphine (placebo; PLB, n = 102). Participants received pharmacotherapy for 8 weeks, with three clinic visits per week. Cognitive behavioral therapy was provided weekly. Follow-up assessments occurred at 1 and 3 months post-intervention. The planned primary outcome was urine drug screen (UDS)-corrected, self-reported cocaine use during the last 4 weeks of treatment. Planned secondary analyses assessed cocaine use by UDS, medication adherence, retention and adverse events. RESULTS: No group differences were found between groups for the primary outcome (BUP4 versus PLB, P = 0.262; BUP16 versus PLB, P = 0.185). Longitudinal analysis of UDS data during the evaluation period using generalized linear mixed equations found a statistically significant difference between BUP16 and PLB [P = 0.022, odds ratio (OR) = 1.71] but not for BUP4 (P = 0.105, OR = 1.05). No secondary outcome differences across groups were found for adherence, retention or adverse events. CONCLUSIONS: Buprenorphine + naloxone, used in combination with naltrexone, may be associated with reductions in cocaine use among people who meet DSM-IV criteria for cocaine dependence and past or current opioid dependence or abuse.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastornos Relacionados con Cocaína / Combinación Buprenorfina y Naloxona / Analgésicos Opioides / Naltrexona / Antagonistas de Narcóticos Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Addiction Asunto de la revista: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastornos Relacionados con Cocaína / Combinación Buprenorfina y Naloxona / Analgésicos Opioides / Naltrexona / Antagonistas de Narcóticos Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Addiction Asunto de la revista: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido